

## COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

## RECENT NEWS

### **Cocrystal's Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants**

Jun 14 2021, 8:30 AM EDT

### **Cocrystal Pharma's Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online**

Jun 9 2021, 2:30 PM EDT

### **Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox**

May 28 2021, 8:00 AM EDT

## STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week Range	\$ - \$

## INVESTOR RELATIONS

LHA Investor Relations  
Jody Cain  
T: 310-691-7100  
[jcain@lhai.com](mailto:jcain@lhai.com)

## MANAGEMENT TEAM

### **Sam Lee, Ph.D.**

Interim Co-Chief Executive Officer and President

### **James J. Martin**

Interim Co-Chief Executive Officer and Chief Financial Officer

## COCRYSTAL PHARMA, INC.

19805 North Creek Parkway  
Bothell, WA 98011  
US

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.